RecruitingNCT04514445

The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.

Bicuspid aoRtic vAlVe gEnetic Research - BRAVE Study


Sponsor

University Hospitals, Leicester

Enrollment

700 participants

Start Date

Sep 8, 2015

Study Type

OBSERVATIONAL

Conditions

Summary

Bicuspid aortic valve (BAV) is the most common congenital heart anomaly in the general population (1-2% of all individuals). In affected people, the aortic valve (the structure ensuring one way blood flow between the heart's left pumping chamber, the left ventricle and the main body artery, the aorta) consists of 2 rather than 3 leaflets. This arrangement can cause the affected valve to have restricted opening or cause it to leak. Both situations put strain on the heart and patients with BAV across the age range may require surgery to replace the affected valve. BAV is therefore a condition associated with significant ill health and early mortality. BAV is known to cluster in families and is likely to have a genetic cause. We don't fully understand the inheritance of BAV or the specific genes involved in its development. Learning more about this is the basis of the BRAVE study. We will ask patients with BAV and their relatives (who may or may not have BAV) to take part in the study. Blood samples obtained from the participants will be used for analyses of their genetic composition. This information, linked with the clinical data concerning who does and does not have BAV, will potentially enable the identification of the gene changes responsible for the disease. This, we hope, will give us a much better understanding of the mechanisms leading to this serious and common condition.


Eligibility

Min Age: 10 YearsMax Age: 99 Years

Inclusion Criteria2

  • \- 1. All outpatients and inpatients with diagnosed BAV, of either gender, aged 10 and above.
  • \. Affected and unaffected first degree relatives meeting the age criteria.

Exclusion Criteria4

  • \) Patients unable to give informed consent.
  • \) Patients known to be infected with HIV, Hepatitis B, Hepatitis C or any other agent posing an infection risk from unfixed material.
  • \) Patient with known cytogenetic disorders e.g. aneuploidia, chromosomal abnormalities and known karyotype abnormalities.
  • \) Patients with diagnosed or suspected Mendelian syndromes (e.g. Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservational

Locations(4)

Kettering General Hospital

Kettering, United Kingdom

University Hospitals of Leicester

Leicester, United Kingdom

Imperial College Healthcare NHS Trust

London, United Kingdom

Sheffield Teaching Hospital NHS Foundation Trust

Sheffield, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04514445


Related Trials